

## VI REFERENCES

1. Zlotnick A: **Are weak protein-protein interactions the general rule in capsid assembly?** *Virology* 2003, **315**:269-274.
2. Ceres P, Zlotnick A: **Weak protein-protein interactions are sufficient to drive assembly of hepatitis B virus capsids.** *Biochemistry* 2002, **41**:11525-11531.
3. Kay MA, Glorioso JC, Naldini L: **Viral vectors for gene therapy: the art of turning infectious agents into vehicles of therapeutics.** *Nat Med* 2001, **7**:33-40.
4. Verma IM: **A tumultuous year for gene therapy.** *Mol Ther* 2000, **2**:415-416.
5. Gansbacher B: **Report of a second serious adverse event in a clinical trial of gene therapy for X-linked severe combined immune deficiency (X-SCID). Position of the European Society of Gene Therapy (ESGT).** *J Gene Med* 2003, **5**:261-262.
6. Lollo CP, Banaszczyk MG, Chiou HC: **Obstacles and advances in non-viral gene delivery.** *Curr Opin Mol Ther* 2000, **2**:136-142.
7. Wagner E, Ogris M, Zauner W: **Polylysine-based transfection systems utilizing receptor-mediated delivery.** *Adv Drug Deliv Rev* 1998, **30**:97-113.
8. Kim SW, Ogawa T, Tabata Y, Nishimura I: **Efficacy and cytotoxicity of cationic-agent-mediated nonviral gene transfer into osteoblasts.** *J Biomed Mater Res* 2004, **71A**:308-315.
9. Dean DA, Machado-Aranda D, Blair-Parks K, Yeldandi AV, Young JL: **Electroporation as a method for high-level nonviral gene transfer to the lung.** *Gene Ther* 2003, **10**:1608-1615.
10. Matsuno Y, Iwata H, Umeda Y, Takagi H, Mori Y, Miyazaki J, Kosugi A, Hirose H: **Nonviral gene gun mediated transfer into the beating heart.** *Asaio J* 2003, **49**:641-644.
11. Schmidt-Wolf GD, Schmidt-Wolf IG: **Non-viral and hybrid vectors in human gene therapy: an update.** *Trends Mol Med* 2003, **9**:67-72.
12. Turk MJ, Reddy JA, Chmielewski JA, Low PS: **Characterization of a novel pH-sensitive peptide that enhances drug release from folate-targeted liposomes at endosomal pHs.** *Biochim Biophys Acta* 2002, **1559**:56-68.
13. Lee H, Jeong JH, Park TG: **A new gene delivery formulation of polyethylenimine/DNA complexes coated with PEG conjugated fusogenic peptide.** *J Control Release* 2001, **76**:183-192.
14. Rittner K, Benavente A, Bompard-Sorlet A, Heitz F, Divita G, Brasseur R, Jacobs E: **New basic membrane-destabilizing peptides for plasmid-based gene delivery in vitro and in vivo.** *Mol Ther* 2002, **5**:104-114.
15. Zabner J, Fasbender AJ, Moninger T, Poellinger KA, Welsh MJ: **Cellular and molecular barriers to gene transfer by a cationic lipid.** *J Biol Chem* 1995, **270**:18997-19007.
16. Niidome T, Huang L: **Gene therapy progress and prospects: nonviral vectors.** *Gene Ther* 2002, **9**:1647-1652.
17. Imamoto N: **Diversity in nucleocytoplasmic transport pathways.** *Cell Struct Funct* 2000, **25**:207-216.
18. Escriou V, Carriere M, Scherman D, Wils P: **NLS bioconjugates for targeting therapeutic genes to the nucleus.** *Adv Drug Deliv Rev* 2003, **55**:295-306.
19. Nishikawa M, Huang L: **Nonviral vectors in the new millennium: delivery barriers in gene transfer.** *Hum Gene Ther* 2001, **12**:861-870.
20. Whittaker GR: **Virus nuclear import.** *Adv Drug Deliv Rev* 2003, **55**:733-747.
21. Whittaker GR, Kann M, Helenius A: **Viral entry into the nucleus.** *Annu Rev Cell Dev Biol* 2000, **16**:627-651.
22. Goff SP: **Intracellular trafficking of retroviral genomes during the early phase of infection: viral exploitation of cellular pathways.** *J Gene Med* 2001, **3**:517-528.
23. Walther W, Stein U, Voss C, Schmidt T, Schlee M, Schlag PM: **Stability analysis for long-term storage of naked DNA: impact on nonviral in vivo gene transfer.** *Anal Biochem* 2003, **318**:230-235.
24. El Mehdaoui S, Touze A, Laurent S, Sizaret PY, Rasschaert D, Coursaget P: **Gene transfer using recombinant rabbit hemorrhagic disease virus capsids with genetically modified DNA encapsidation capacity by addition of packaging**

- sequences from the L1 or L2 protein of human papillomavirus type 16. *J Virol* 2000, **74**:10332-10340.
25. Cho CW, Cho YS, Kang BT, Hwang JS, Park SN, Yoon DY: **Improvement of gene transfer to cervical cancer cell lines using non-viral agents.** *Cancer Lett* 2001, **162**:75-85.
26. Yamada T, Iwasaki Y, Tada H, Iwabuki H, Chuah MK, VandenDriessche T, Fukuda H, Kondo A, Ueda M, Seno M, et al.: **Nanoparticles for the delivery of genes and drugs to human hepatocytes.** *Nat Biotechnol* 2003, **21**:885-890.
27. Joliot A, Prochiantz A: **Transduction peptides: from technology to physiology.** *Nat Cell Biol* 2004, **6**:189-196.
28. Jarver P, Langel U: **The use of cell-penetrating peptides as a tool for gene regulation.** *Drug Discov Today* 2004, **9**:395-402.
29. Frankel AD, Pabo CO: **Cellular uptake of the tat protein from human immunodeficiency virus.** *Cell* 1988, **55**:1189-1193.
30. Joliot A, Pernelle C, Deagostini-Bazin H, Prochiantz A: **Antennapedia homeobox peptide regulates neural morphogenesis.** *Proc Natl Acad Sci U S A* 1991, **88**:1864-1868.
31. Derossi D, Joliot AH, Chassaing G, Prochiantz A: **The third helix of the Antennapedia homeodomain translocates through biological membranes.** *J Biol Chem* 1994, **269**:10444-10450.
32. Vives E, Brodin P, Lebleu B: **A truncated HIV-1 Tat protein basic domain rapidly translocates through the plasma membrane and accumulates in the cell nucleus.** *J Biol Chem* 1997, **272**:16010-16017.
33. Oehlke J, Scheller A, Wiesner B, Krause E, Beyermann M, Klauschenz E, Melzig M, Bienert M: **Cellular uptake of an alpha-helical amphipathic model peptide with the potential to deliver polar compounds into the cell interior non-endocytically.** *Biochim Biophys Acta* 1998, **1414**:127-139.
34. Pooga M, Soomets U, Hallbrink M, Valkna A, Saar K, Rezaei K, Kahl U, Hao JX, Xu XJ, Wiesenfeld-Hallin Z, et al.: **Cell penetrating PNA constructs regulate galanin receptor levels and modify pain transmission in vivo.** *Nat Biotechnol* 1998, **16**:857-861.
35. Soomets U, Lindgren M, Gallet X, Hallbrink M, Elmquist A, Balaspiri L, Zorko M, Pooga M, Brasseur R, Langel U: **Deletion analogues of transportan.** *Biochim Biophys Acta* 2000, **1467**:165-176.
36. Rothbard JB, Garlington S, Lin Q, Kirschberg T, Kreider E, McGrane PL, Wender PA, Khavari PA: **Conjugation of arginine oligomers to cyclosporin A facilitates topical delivery and inhibition of inflammation.** *Nat Med* 2000, **6**:1253-1257.
37. Elmquist A, Lindgren M, Bartfai T, Langel U: **VE-cadherin-derived cell-penetrating peptide, pVEC, with carrier functions.** *Exp Cell Res* 2001, **269**:237-244.
38. Morris MC, Vidal P, Chaloin L, Heitz F, Divita G: **A new peptide vector for efficient delivery of oligonucleotides into mammalian cells.** *Nucleic Acids Res* 1997, **25**:2730-2736.
39. Wyman TB, Nicol F, Zelphati O, Scaria PV, Plank C, Szoka FC, Jr.: **Design, synthesis, and characterization of a cationic peptide that binds to nucleic acids and permeabilizes bilayers.** *Biochemistry* 1997, **36**:3008-3017.
40. Takeshima K, Chikushi A, Lee KK, Yonehara S, Matsuzaki K: **Translocation of analogues of the antimicrobial peptides magainin and buforin across human cell membranes.** *J Biol Chem* 2003, **278**:1310-1315.
41. Richard JP, Melikov K, Vives E, Ramos C, Verbeure B, Gait MJ, Chernomordik LV, Lebleu B: **Cell-penetrating peptides. A reevaluation of the mechanism of cellular uptake.** *J Biol Chem* 2003, **278**:585-590.
42. Lundberg M, Wikstrom S, Johansson M: **Cell surface adherence and endocytosis of protein transduction domains.** *Mol Ther* 2003, **8**:143-150.
43. Vives E, Richard JP, Rispal C, Lebleu B: **TAT peptide internalization: seeking the mechanism of entry.** *Curr Protein Pept Sci* 2003, **4**:125-132.
44. Drin G, Cottin S, Blanc E, Rees AR, Tamsamani J: **Studies on the internalization mechanism of cationic cell-penetrating peptides.** *J Biol Chem* 2003, **278**:31192-31201.

45. Fischer R, Kohler K, Fotin-Mleczek M, Brock R: **A stepwise dissection of the intracellular fate of cationic cell-penetrating peptides.** *J Biol Chem* 2004, **279**:12625-12635.
46. Jo D, Nashabi A, Doxsee C, Lin Q, Unutmaz D, Chen J, Ruley HE: **Epigenetic regulation of gene structure and function with a cell-permeable Cre recombinase.** *Nat Biotechnol* 2001, **19**:929-933.
47. Peitz M, Pfannkuche K, Rajewsky K, Edenhofer F: **Ability of the hydrophobic FGF and basic TAT peptides to promote cellular uptake of recombinant Cre recombinase: a tool for efficient genetic engineering of mammalian genomes.** *Proc Natl Acad Sci U S A* 2002, **99**:4489-4494.
48. Cao G, Pei W, Ge H, Liang Q, Luo Y, Sharp FR, Lu A, Ran R, Graham SH, Chen J: **In Vivo Delivery of a Bcl-xL Fusion Protein Containing the TAT Protein Transduction Domain Protects against Ischemic Brain Injury and Neuronal Apoptosis.** *J Neurosci* 2002, **22**:5423-5431.
49. Borsello T, Bonny C: **Use of cell-permeable peptides to prevent neuronal degeneration.** *Trends Mol Med* 2004, **10**:239-244.
50. Wadkins TS, Been MD: **Core-associated non-duplex sequences distinguishing the genomic and antigenomic self-cleaving RNAs of hepatitis delta virus.** *Nucleic Acids Res* 1997, **25**:4085-4092.
51. Marcucci F, Lefoulon F: **Active targeting with particulate drug carriers in tumor therapy: fundamentals and recent progress.** *Drug Discov Today* 2004, **9**:219-228.
52. Oess S, Hildt E: **Novel cell permeable motif derived from the PreS2-domain of hepatitis-B virus surface antigens.** *Gene Ther* 2000, **7**:750-758.
53. Saher G, Hildt E: **Activation of c-Raf-1 kinase signal transduction pathway in alpha(7) integrin-deficient mice.** *J Biol Chem* 1999, **274**:27651-27657.
54. Hafner A, Brandenburg B, Hildt E: **Reconstitution of gene expression from a regulatory-protein-deficient hepatitis B virus genome by cell-permeable HBx protein.** *EMBO Rep* 2003, **4**:767-773.
55. Deshayes S, Plenat T, Aldrian-Herrada G, Divita G, Le Grimmellec C, Heitz F: **Primary amphipathic cell-penetrating peptides: structural requirements and interactions with model membranes.** *Biochemistry* 2004, **43**:7698-7706.
56. Hildt E, Urban S, Hofschneider PH: **Characterization of essential domains for the functionality of the MHBst transcriptional activator and identification of a minimal MHBst activator.** *Oncogene* 1995, **11**:2055-2066.
57. Breiner KM, Urban S, Schaller H: **Carboxypeptidase D (gp180), a Golgi-resident protein, functions in the attachment and entry of avian hepatitis B viruses.** *J Virol* 1998, **72**:8098-8104.
58. Breiner KM, Schaller H: **Cellular receptor traffic is essential for productive duck hepatitis B virus infection.** *J Virol* 2000, **74**:2203-2209.
59. Kock J, Borst EM, Schlicht HJ: **Uptake of duck hepatitis B virus into hepatocytes occurs by endocytosis but does not require passage of the virus through an acidic intracellular compartment.** *J Virol* 1996, **70**:5827-5831.
60. Funk A, Mhamdi M, Lin L, Will H, Sirma H: **Itinerary of hepatitis B viruses: delineation of restriction points critical for infectious entry.** *J Virol* 2004, **78**:8289-8300.
61. Stoeckl L, Funk F, Kopitzki A, Brandenburg B, Oess S, Will H, Sirma H, Hildt E: **Identification of a novel structural motif crucial for infectivity of hepatitis B viruses.** *submitted to PNAS* 2005.
62. Klenk HD, Rott R, Orlich M, Blodorn J: **Activation of influenza A viruses by trypsin treatment.** *Virology* 1975, **68**:426-439.
63. Skehel JJ, Wiley DC: **Receptor binding and membrane fusion in virus entry: the influenza hemagglutinin.** *Annu Rev Biochem* 2000, **69**:531-569.
64. Belnap DM, Filman DJ, Trus BL, Cheng N, Booy FP, Conway JF, Curry S, Hiremath CN, Tsang SK, Steven AC, et al.: **Molecular tectonic model of virus structural transitions: the putative cell entry states of poliovirus.** *J Virol* 2000, **74**:1342-1354.
65. Fricks CE, Hogle JM: **Cell-induced conformational change in poliovirus: externalization of the amino terminus of VP1 is responsible for liposome binding.** *J Virol* 1990, **64**:1934-1945.

66. Pumpens P, Grens E: **HBV core particles as a carrier for B cell/T cell epitopes.** *Intervirology* 2001, **44**:98-114.
67. Kratz PA, Bottcher B, Nassal M: **Native display of complete foreign protein domains on the surface of hepatitis B virus capsids.** *Proc Natl Acad Sci U S A* 1999, **96**:1915-1920.
68. Ott MJ, Aruda M: **Hepatitis B vaccine.** *J Pediatr Health Care* 1999, **13**:211-216.
69. Zuckerman AJ: **More than third of world's population has been infected with hepatitis B virus.** *Bmj* 1999, **318**:1213.
70. World Health Organisation: **World Health Report 2002.** [http://www.who.int/emc-documents/hepatitis/docs/whocdscrlyo20022/surveillance/incidence\\_epidemiology.html](http://www.who.int/emc-documents/hepatitis/docs/whocdscrlyo20022/surveillance/incidence_epidemiology.html) 2002, **04-12-2004**.
71. Summers J, Smolec JM, Snyder R: **A virus similar to human hepatitis B virus associated with hepatitis and hepatoma in woodchucks.** *Proc Natl Acad Sci U S A* 1978, **75**:4533-4537.
72. Marion PL, Oshiro LS, Regnery DC, Scullard GH, Robinson WS: **A virus in Beechey ground squirrels that is related to hepatitis B virus of humans.** *Proc Natl Acad Sci U S A* 1980, **77**:2941-2945.
73. Mason WS, Seal G, Summers J: **Virus of Pekin ducks with structural and biological relatedness to human hepatitis B virus.** *J Virol* 1980, **36**:829-836.
74. Sprengel R, Kaleta EF, Will H: **Isolation and characterization of a hepatitis B virus endemic in herons.** *J Virol* 1988, **62**:3832-3839.
75. Galle PR, Hagelstein J, Kommerell B, Volkmann M, Schranz P, Zentgraf H: **In vitro experimental infection of primary human hepatocytes with hepatitis B virus.** *Gastroenterology* 1994, **106**:664-673.
76. Delaney WEt, Isom HC: **Hepatitis B virus replication in human HepG2 cells mediated by hepatitis B virus recombinant baculovirus.** *Hepatology* 1998, **28**:1134-1146.
77. Gripon P, Diot C, Guguen-Guillouzo C: **Reproducible high level infection of cultured adult human hepatocytes by hepatitis B virus: effect of polyethylene glycol on adsorption and penetration.** *Virology* 1993, **192**:534-540.
78. Gripon P, Rumin S, Urban S, Le Seyec J, Glaise D, Cannie I, Guyomard C, Lucas J, Treppe C, Guguen-Guillouzo C: **Infection of a human hepatoma cell line by hepatitis B virus.** *Proc Natl Acad Sci U S A* 2002, **99**:15655-15660.
79. Mandart E, Kay A, Galibert F: **Nucleotide sequence of a cloned duck hepatitis B virus genome: comparison with woodchuck and human hepatitis B virus sequences.** *J Virol* 1984, **49**:782-792.
80. Feitelson MA, Larkin JD: **New animal models of hepatitis B and C.** *Ilar J* 2001, **42**:127-138.
81. Ribeiro RM, Lo A, Perelson AS: **Dynamics of hepatitis B virus infection.** *Microbes Infect* 2002, **4**:829-835.
82. Dane DS, Cameron CH, Briggs M: **Virus-like particles in serum of patients with Australia-antigen-associated hepatitis.** *Lancet* 1970, **1**:695-698.
83. Perkins JA: **Infectious disease - HBV.** <http://www.rit.edu/~japfaa/infectious.html> 2002.
84. Neurath AR, Strick N: **The putative cell receptors for hepatitis B virus (HBV), annexin V, and apolipoprotein H, bind to lipid components of HBV.** *Virology* 1994, **204**:475-477.
85. Paran N, Geiger B, Shaul Y: **HBV infection of cell culture: evidence for multivalent and cooperative attachment.** *Embo J* 2001, **20**:4443-4453.
86. Glebe D, Aliakbari M, Krass P, Knoop EV, Valerius KP, Gerlich WH: **Pre-s1 antigen-dependent infection of Tupaia hepatocyte cultures with human hepatitis B virus.** *J Virol* 2003, **77**:9511-9521.
87. Urban S, Breiner KM, Fehler F, Klingmuller U, Schaller H: **Avian hepatitis B virus infection is initiated by the interaction of a distinct pre-S subdomain with the cellular receptor gp180.** *J Virol* 1998, **72**:8089-8097.
88. Tong S, Li J, Wands JR: **Carboxypeptidase D is an avian hepatitis B virus receptor.** *J Virol* 1999, **73**:8696-8702.
89. Urban S, Schwarz C, Marx UC, Zentgraf H, Schaller H, Multhaup G: **Receptor recognition by a hepatitis B virus reveals a novel mode of high affinity virus-receptor interaction.** *Embo J* 2000, **19**:1217-1227.

90. Urban S, Gripon P: **Inhibition of duck hepatitis B virus infection by a myristoylated pre-S peptide of the large viral surface protein.** *J Virol* 2002, **76**:1986-1990.
91. Carr CM, Chaudhry C, Kim PS: **Influenza hemagglutinin is spring-loaded by a metastable native conformation.** *Proc Natl Acad Sci U S A* 1997, **94**:14306-14313.
92. Eckhardt SG, Milich DR, McLachlan A: **Hepatitis B virus core antigen has two nuclear localization sequences in the arginine-rich carboxyl terminus.** *J Virol* 1991, **65**:575-582.
93. Bock CT, Schwinn S, Schroder CH, Velhagen I, Zentgraf H: **Localization of hepatitis B virus core protein and viral DNA at the nuclear membrane.** *Virus Genes* 1996, **12**:53-63.
94. Kann M, Sodeik B, Vlachou A, Gerlich WH, Helenius A: **Phosphorylation-dependent binding of hepatitis B virus core particles to the nuclear pore complex.** *J Cell Biol* 1999, **145**:45-55.
95. Kann M, Gerlich WH: **Effect of core protein phosphorylation by protein kinase C on encapsidation of RNA within core particles of hepatitis B virus.** *J Virol* 1994, **68**:7993-8000.
96. Ruiz-Opazo N, Chakraborty PR, Shafritz DA: **Evidence for supercoiled hepatitis B virus DNA in chimpanzee liver and serum Dane particles: possible implications in persistent HBV infection.** *Cell* 1982, **29**:129-136.
97. Schaller H, Fischer M: **Transcriptional control of hepadnavirus gene expression.** *Curr Top Microbiol Immunol* 1991, **168**:21-39.
98. Bartenschlager R, Junker-Niepmann M, Schaller H: **The P gene product of hepatitis B virus is required as a structural component for genomic RNA encapsidation.** *J Virol* 1990, **64**:5324-5332.
99. Nassal M, Schaller H: **Hepatitis B virus replication--an update.** *J Viral Hepat* 1996, **3**:217-226.
100. Huovila AP, Eder AM, Fuller SD: **Hepatitis B surface antigen assembles in a post-ER, pre-Golgi compartment.** *J Cell Biol* 1992, **118**:1305-1320.
101. Weinberg M: **Hepatitis B Virus life-cycle.** <http://hbvrp.wits.ac.za/websitetut5.htm> 2002.
102. Lu X, Block T: **Study of the early steps of the Hepatitis B Virus life cycle.** *Int. J. Med. Sci.* 2004, **1**:21-33.
103. Robinson WS, Clayton DA, Greenman RL: **DNA of a human hepatitis B virus candidate.** *J Virol* 1974, **14**:384-391.
104. Wen YM: **Structural and functional analysis of full-length hepatitis B virus genomes in patients: implications in pathogenesis.** *J Gastroenterol Hepatol* 2004, **19**:485-489.
105. Galibert F, Mandart E, Fitoussi F, Tiollais P, Charnay P: **Nucleotide sequence of the hepatitis B virus genome (subtype ayw) cloned in E. coli.** *Nature* 1979, **281**:646-650.
106. Seeger C, Mason WS: **Hepatitis B virus biology.** *Microbiol Mol Biol Rev* 2000, **64**:51-68.
107. Chisari FV: **Rous-Whipple Award Lecture. Viruses, immunity, and cancer: lessons from hepatitis B.** *Am J Pathol* 2000, **156**:1117-1132.
108. Norder H, Courouce AM, Coursaget P, Echevarria JM, Lee SD, Mushahwar IK, Robertson BH, Locarnini S, Magnius LO: **Genetic diversity of hepatitis B virus strains derived worldwide: genotypes, subgenotypes, and HBsAg subtypes.** *Intervirology* 2004, **47**:289-309.
109. Scaglioni PP, Melegari M, Wands JR: **Posttranscriptional regulation of hepatitis B virus replication by the precore protein.** *J Virol* 1997, **71**:345-353.
110. Lachmann S, Meisel H, Muselmann C, Koletzki D, Gelderblom HR, Borisova G, Kruger DH, Pumpens P, Ulrich R: **Characterization of potential insertion sites in the core antigen of hepatitis B virus by the use of a short-sized model epitope.** *Intervirology* 1999, **42**:51-56.
111. Wynne SA, Crowther RA, Leslie AG: **The crystal structure of the human hepatitis B virus capsid.** *Mol Cell.* 1999, **3**:771-780.
112. Bottcher B, Wynne SA, Crowther RA: **Determination of the fold of the core protein of hepatitis B virus by electron cryomicroscopy.** *Nature* 1997, **386**:88-91.

113. Pumpens P, Grens E: **Hepatitis B core particles as a universal display model: a structure-function basis for development.** *FEBS Lett* 1999, **442**:1-6.
114. Zlotnick A, Palmer I, Kaufman JD, Stahl SJ, Steven AC, Wingfield PT: **Separation and crystallization of T = 3 and T = 4 icosahedral complexes of the hepatitis B virus core protein.** *Acta Crystallogr D Biol Crystallogr* 1999, **55 ( Pt 3)**:717-720.
115. Gallina A, Bonelli F, Zentilin L, Rindi G, Muttini M, Milanese G: **A recombinant hepatitis B core antigen polypeptide with the protamine-like domain deleted self-assembles into capsid particles but fails to bind nucleic acids.** *J Virol* 1989, **63**:4645-4652.
116. Crowther RA, Kiselev NA, Bottcher B, Berriman JA, Borisova GP, Ose V, Pumpens P: **Three-dimensional structure of hepatitis B virus core particles determined by electron cryomicroscopy.** *Cell* 1994, **77**:943-950.
117. Birnbaum F, Nassal M: **Hepatitis B virus nucleocapsid assembly: primary structure requirements in the core protein.** *J Virol* 1990, **64**:3319-3330.
118. Zlotnick A, Cheng N, Conway JF, Booy FP, Steven AC, Stahl SJ, Wingfield PT: **Dimorphism of hepatitis B virus capsids is strongly influenced by the C-terminus of the capsid protein.** *Biochemistry* 1996, **35**:7412-7421.
119. Koschel M, Thomssen R, Bruss V: **Extensive mutagenesis of the hepatitis B virus core gene and mapping of mutations that allow capsid formation.** *J Virol* 1999, **73**:2153-2160.
120. Poisson F, Severac A, Hourieux C, Goudeau A, Roingeard P: **Both pre-S1 and S domains of hepatitis B virus envelope proteins interact with the core particle.** *Virology* 1997, **228**:115-120.
121. Choi KJ, Lim CW, Yoon MY, Ahn BY, Yu YG: **Quantitative analysis of the interaction between the envelope protein domains and the core protein of human hepatitis B virus.** *Biochem Biophys Res Commun* 2004, **319**:959-966.
122. Bottcher B, Tsuji N, Takahashi H, Dyson MR, Zhao S, Crowther RA, Murray K: **Peptides that block hepatitis B virus assembly: analysis by cryomicroscopy, mutagenesis and transfection.** *Embo J* 1998, **17**:6839-6845.
123. Duclos-Vallee JC, Capel F, Mabit H, Petit MA: **Phosphorylation of the hepatitis B virus core protein by glyceraldehyde-3-phosphate dehydrogenase protein kinase activity.** *J Gen Virol* 1998, **79 ( Pt 7)**:1665-1670.
124. Daub H, Blencke S, Habenberger P, Kurtenbach A, Dennenmoser J, Wissing J, Ullrich A, Cotten M: **Identification of SRPK1 and SRPK2 as the major cellular protein kinases phosphorylating hepatitis B virus core protein.** *J Virol* 2002, **76**:8124-8137.
125. Kann M, Thomssen R, Kochel HG, Gerlich WH: **Characterization of the endogenous protein kinase activity of the hepatitis B virus.** *Arch Virol Suppl* 1993, **8**:53-62.
126. Liao W, Ou JH: **Phosphorylation and nuclear localization of the hepatitis B virus core protein: significance of serine in the three repeated SPRRR motifs.** *J Virol* 1995, **69**:1025-1029.
127. Lan YT, Li J, Liao W, Ou J: **Roles of the three major phosphorylation sites of hepatitis B virus core protein in viral replication.** *Virology* 1999, **259**:342-348.
128. Gazina EV, Fielding JE, Lin B, Anderson DA: **Core protein phosphorylation modulates pregenomic RNA encapsidation to different extents in human and duck hepatitis B viruses.** *J Virol* 2000, **74**:4721-4728.
129. Hui EK, Chen KL, Lo SJ: **Hepatitis B virus maturation is affected by the incorporation of core proteins having a C-terminal substitution of arginine or lysine stretches.** *J Gen Virol* 1999, **80 ( Pt 10)**:2661-2671.
130. Zlotnick A, Johnson JM, Wingfield PW, Stahl SJ, Endres D: **A theoretical model successfully identifies features of hepatitis B virus capsid assembly.** *Biochemistry* 1999, **38**:14644-14652.
131. Kamimura T, Yoshikawa A, Ichida F, Sasaki H: **Electron microscopic studies of Dane particles in hepatocytes with special reference to intracellular development of Dane particles and their relation with HBeAg in serum.** *Hepatology* 1981, **1**:392-397.
132. Hildt E, Munz B, Saher G, Reifenberg K, Hofschneider PH: **The PreS2 activator MHBs(t) of hepatitis B virus activates c-raf-1/Erk2 signaling in transgenic mice.** *Embo J* 2002, **21**:525-535.

133. Heermann KH, Kruse F, Seifer M, Gerlich WH: **Immunogenicity of the gene S and Pre-S domains in hepatitis B virions and HBsAg filaments.** *Intervirology* 1987, **28**:14-25.
134. Nassal M: **Hepatitis B virus replication: novel roles for virus-host interactions.** *Intervirology* 1999, **42**:100-116.
135. Paran N, Cooper A, Shaul Y: **Interaction of hepatitis B virus with cells.** *Rev Med Virol* 2003, **13**:137-143.
136. Park SG, Kim Y, Park E, Ryu HM, Jung G: **Fidelity of hepatitis B virus polymerase.** *Eur J Biochem* 2003, **270**:2929-2936.
137. Junker-Niepmann M, Bartenschlager R, Schaller H: **A short cis-acting sequence is required for hepatitis B virus pregenome encapsidation and sufficient for packaging of foreign RNA.** *Embo J* 1990, **9**:3389-3396.
138. Pollack JR, Ganem D: **Site-specific RNA binding by a hepatitis B virus reverse transcriptase initiates two distinct reactions: RNA packaging and DNA synthesis.** *J Virol* 1994, **68**:5579-5587.
139. Jeong JK, Yoon GS, Ryu WS: **Evidence that the 5'-end cap structure is essential for encapsidation of hepatitis B virus pregenomic RNA.** *J Virol* 2000, **74**:5502-5508.
140. Fallows DA, Goff SP: **Mutations in the epsilon sequences of human hepatitis B virus affect both RNA encapsidation and reverse transcription.** *J Virol* 1995, **69**:3067-3073.
141. Havert MB, Loeb DD: **cis-Acting sequences in addition to donor and acceptor sites are required for template switching during synthesis of plus-strand DNA for duck hepatitis B virus.** *J Virol* 1997, **71**:5336-5344.
142. Seeger C, Ganem D, Varmus HE: **Biochemical and genetic evidence for the hepatitis B virus replication strategy.** *Science* 1986, **232**:477-484.
143. Zoulim F, Saputelli J, Seeger C: **Woodchuck hepatitis virus X protein is required for viral infection in vivo.** *J Virol* 1994, **68**:2026-2030.
144. Caselmann WH: **Trans-activation of cellular genes by hepatitis B virus proteins: a possible mechanism of hepatocarcinogenesis.** *Adv Virus Res* 1996, **47**:253-302.
145. Reifenberg K, Wilts H, Lohler J, Nusser P, Hanano R, Guidotti LG, Chisari FV, Schlicht HJ: **The hepatitis B virus X protein transactivates viral core gene expression in vivo.** *J Virol* 1999, **73**:10399-10405.
146. Waris G, Siddiqui A: **Regulatory mechanisms of viral hepatitis B and C.** *J Biosci* 2003, **28**:311-321.
147. Eckert DM, Kim PS: **Mechanisms of viral membrane fusion and its inhibition.** *Annu Rev Biochem* 2001, **70**:777-810.
148. Cullen BR: **Journey to the center of the cell.** *Cell* 2001, **105**:697-700.
149. Formanowski F, Wharton SA, Calder LJ, Hofbauer C, Meier-Ewert H: **Fusion characteristics of influenza C viruses.** *J Gen Virol* 1990, **71 ( Pt 5)**:1181-1188.
150. Lobigs M, Garoff H: **Fusion function of the Semliki Forest virus spike is activated by proteolytic cleavage of the envelope glycoprotein precursor p62.** *J Virol* 1990, **64**:1233-1240.
151. Sodeik B: **Mechanisms of viral transport in the cytoplasm.** *Trends Microbiol* 2000, **8**:465-472.
152. Tomishima MJ, Smith GA, Enquist LW: **Sorting and transport of alpha herpesviruses in axons.** *Traffic* 2001, **2**:429-436.
153. Dohner K, Sodeik B: **The role of the cytoskeleton during viral infection.** *Curr Top Microbiol Immunol* 2005, **285**:67-108.
154. Cudmore S, Cossart P, Griffiths G, Way M: **Actin-based motility of vaccinia virus.** *Nature* 1995, **378**:636-638.
155. Marsh M, Bron R: **SFV infection in CHO cells: cell-type specific restrictions to productive virus entry at the cell surface.** *J Cell Sci* 1997, **110 ( Pt 1)**:95-103.
156. Pelkmans L, Puntener D, Helenius A: **Local actin polymerization and dynamin recruitment in SV40-induced internalization of caveolae.** *Science* 2002, **296**:535-539.
157. Smith AE, Helenius A: **How viruses enter animal cells.** *Science* 2004, **304**:237-242.
158. Lakadamyali M, Rust MJ, Babcock HP, Zhuang X: **Visualizing infection of individual influenza viruses.** *Proc Natl Acad Sci U S A* 2003, **100**:9280-9285.

159. Lanier LM, Volkman LE: **Actin binding and nucleation by Autographa californica M nucleopolyhedrovirus.** *Virology* 1998, **243**:167-177.
160. Lanier LM, Slack JM, Volkman LE: **Actin binding and proteolysis by the baculovirus AcMNPV: the role of virion-associated V-CATH.** *Virology* 1996, **216**:380-388.
161. Siczekarski SB, Whittaker GR: **Viral entry.** *Curr Top Microbiol Immunol* 2005, **285**:1-23.
162. Merle E, Rose RC, LeRoux L, Moroianu J: **Nuclear import of HPV11 L1 capsid protein is mediated by karyopherin alpha2beta1 heterodimers.** *J Cell Biochem* 1999, **74**:628-637.
163. Nelson LM, Rose RC, LeRoux L, Lane C, Bruya K, Moroianu J: **Nuclear import and DNA binding of human papillomavirus type 45 L1 capsid protein.** *J Cell Biochem* 2000, **79**:225-238.
164. Trotman LC, Mosberger N, Fornerod M, Stidwill RP, Greber UF: **Import of adenovirus DNA involves the nuclear pore complex receptor CAN/Nup214 and histone H1.** *Nat Cell Biol* 2001, **3**:1092-1100.
165. Dworetzky SI, Feldherr CM: **Translocation of RNA-coated gold particles through the nuclear pores of oocytes.** *J Cell Biol* 1988, **106**:575-584.
166. Bustamante JO, Varanda WA: **Patch-clamp detection of macromolecular translocation along nuclear pores.** *Braz J Med Biol Res* 1998, **31**:333-354.
167. Bustamante JO, Michelette ER, Geibel JP, Hanover JA, McDonnell TJ, Dean DA: **Dendrimer-assisted patch-clamp sizing of nuclear pores.** *Pflugers Arch* 2000, **439**:829-837.
168. Pante N, Kann M: **Nuclear pore complex is able to transport macromolecules with diameters of about 39 nm.** *Mol Biol Cell* 2002, **13**:425-434.
169. Rabe B, Vlachou A, Pante N, Helenius A, Kann M: **Nuclear import of hepatitis B virus capsids and release of the viral genome.** *Proc Natl Acad Sci U S A* 2003, **100**:9849-9854.
170. Greber UF, Fornerod M: **Nuclear import in viral infections.** *Curr Top Microbiol Immunol* 2005, **285**:109-138.
171. Greber UF, Fassati A: **Nuclear import of viral DNA genomes.** *Traffic* 2003, **4**:136-143.
172. Ojala PM, Sodeik B, Ebersold MW, Kutay U, Helenius A: **Herpes simplex virus type 1 entry into host cells: reconstitution of capsid binding and uncoating at the nuclear pore complex in vitro.** *Mol Cell Biol* 2000, **20**:4922-4931.
173. Sodeik B, Ebersold MW, Helenius A: **Microtubule-mediated transport of incoming herpes simplex virus 1 capsids to the nucleus.** *J Cell Biol* 1997, **136**:1007-1021.
174. Zlotnick A, Cheng N, Stahl SJ, Conway JF, Steven AC, Wingfield PT: **Localization of the C terminus of the assembly domain of hepatitis B virus capsid protein: implications for morphogenesis and organization of encapsidated RNA.** *Proc Natl Acad Sci U S A* 1997, **94**:9556-9561.
175. Ponsel D, Bruss V: **Mapping of amino acid side chains on the surface of hepatitis B virus capsids required for envelopment and virion formation.** *J Virol* 2003, **77**:416-422.
176. Conway JF, Cheng N, Zlotnick A, Stahl SJ, Wingfield PT, Steven AC: **Localization of the N terminus of hepatitis B virus capsid protein by peptide-based difference mapping from cryoelectron microscopy.** *Proc Natl Acad Sci U S A* 1998, **95**:14622-14627.
177. Zlotnick A, Ceres P, Singh S, Johnson JM: **A small molecule inhibits and misdirects assembly of hepatitis B virus capsids.** *J Virol* 2002, **76**:4848-4854.
178. Singh S, Zlotnick A: **Observed hysteresis of virus capsid disassembly is implicit in kinetic models of assembly.** *J Biol Chem* 2003, **278**:18249-18255.
179. Pas SD, Niesters HG: **Detection of HBV DNA using real time analysis.** *J Clin Virol* 2002, **25**:93-94.
180. Hillemann A, Brandenburg B, Schmidt U, Roos M, Smirnow I, Lemken M, Lauer UM, Hildt E: **Protein transduction with bacterial cytosine deaminase fused to the TLM intercellular transport motif induces profound chemosensitivity to 5-fluorocytosine in human hepatoma cells.** *Journal of Hepatology* 2005:in press.
181. Hu K, Beck J, Nassal M: **SELEX-derived aptamers of the duck hepatitis B virus RNA encapsidation signal distinguish critical and non-critical residues for**



- productive initiation of reverse transcription.** *Nucleic Acids Res* 2004, **32**:4377-4389.
182. Conway JF, Watts NR, Belnap DM, Cheng N, Stahl SJ, Wingfield PT, Steven AC: **Characterization of a conformational epitope on hepatitis B virus core antigen and quasiequivalent variations in antibody binding.** *J Virol* 2003, **77**:6466-6473.
183. Rothenberger S, Iacopetta BJ, Kuhn LC: **Endocytosis of the transferrin receptor requires the cytoplasmic domain but not its phosphorylation site.** *Cell* 1987, **49**:423-431.
184. Dautry-Varsat A: **Receptor-mediated endocytosis: the intracellular journey of transferrin and its receptor.** *Biochimie* 1986, **68**:375-381.
185. Yamashiro DJ, Tycko B, Fluss SR, Maxfield FR: **Segregation of transferrin to a mildly acidic (pH 6.5) para-Golgi compartment in the recycling pathway.** *Cell* 1984, **37**:789-800.
186. Nicola AV, McEvoy AM, Straus SE: **Roles for endocytosis and low pH in herpes simplex virus entry into HeLa and Chinese hamster ovary cells.** *J Virol* 2003, **77**:5324-5332.
187. Klausner RD, Van Renswoude J, Ashwell G, Kempf C, Schechter AN, Dean A, Bridges KR: **Receptor-mediated endocytosis of transferrin in K562 cells.** *J Biol Chem* 1983, **258**:4715-4724.
188. Kuismanen E, Saraste J: **Low temperature-induced transport blocks as tools to manipulate membrane traffic.** *Methods Cell Biol* 1989, **32**:257-274.
189. Pastan IH, Willingham MC: **Journey to the center of the cell: role of the receptosome.** *Science* 1981, **214**:504-509.
190. Lott L, Beames B, Notvall L, Lanford RE: **Interaction between hepatitis B virus core protein and reverse transcriptase.** *J Virol* 2000, **74**:11479-11489.
191. Untergasser A, Protzer U: **Hepatitis B virus-based vectors allow the elimination of viral gene expression and the insertion of foreign promoters.** *Hum Gene Ther* 2004, **15**:203-210.
192. Bartenschlager R, Schaller H: **Hepadnaviral assembly is initiated by polymerase binding to the encapsidation signal in the viral RNA genome.** *Embo J* 1992, **11**:3413-3420.
193. Ziermann R, Ganem D: **Homologous and heterologous complementation of HBV and WHV capsid and polymerase functions in RNA encapsidation.** *Virology* 1996, **219**:350-356.
194. Whittaker GR, Helenius A: **Nuclear import and export of viruses and virus genomes.** *Virology* 1998, **246**:1-23.
195. Mabit H, Nakano MY, Prank U, Saam B, Dohner K, Sodeik B, Greber UF: **Intact microtubules support adenovirus and herpes simplex virus infections.** *J Virol* 2002, **76**:9962-9971.
196. Dohner K, Wolfstein A, Prank U, Echeverri C, Dujardin D, Vallee R, Sodeik B: **Function of dynein and dynactin in herpes simplex virus capsid transport.** *Mol Biol Cell* 2002, **13**:2795-2809.
197. Bartlett JS, Wilcher R, Samulski RJ: **Infectious entry pathway of adeno-associated virus and adeno-associated virus vectors.** *J Virol* 2000, **74**:2777-2785.
198. Beck M, Forster F, Ecke M, Plitzko JM, Melchior F, Gerisch G, Baumeister W, Medalia O: **Nuclear pore complex structure and dynamics revealed by cryoelectron tomography.** *Science* 2004, **306**:1387-1390.
199. Comanescu V, Ardeleanu C, Zaharia B, Florescu M, Simionescu C, Comanescu C: **Histopathologic and immunohistochemic correlations in virus B chronic hepatitis.** *Rom J Morphol Embryol* 1997, **43**:169-172.
200. Serinoz E, Varli M, Erden E, Cinar K, Kansu A, Uzunalimoglu O, Yurdaydin C, Bozkaya H: **Nuclear localization of hepatitis B core antigen and its relations to liver injury, hepatocyte proliferation, and viral load.** *J Clin Gastroenterol* 2003, **36**:269-272.
201. Adam SA, Marr RS, Gerace L: **Nuclear protein import in permeabilized mammalian cells requires soluble cytoplasmic factors.** *J Cell Biol* 1990, **111**:807-816.
202. Kim SH, Kim S, Robbins PD: **Retroviral vectors.** *Adv Virus Res* 2000, **55**:545-563.

203. Baum C, von Kalle C, Staal FJ, Li Z, Fehse B, Schmidt M, Weerkamp F, Karlsson S, Wagemaker G, Williams DA: **Chance or necessity? Insertional mutagenesis in gene therapy and its consequences.** *Mol Ther* 2004, **9**:5-13.
204. Mukherjee S, Ghosh RN, Maxfield FR: **Endocytosis.** *Physiol Rev* 1997, **77**:759-803.
205. Lindgren M, Hallbrink M, Prochiantz A, Langel U: **Cell-penetrating peptides.** *Trends Pharmacol Sci* 2000, **21**:99-103.
206. Dunican DJ, Doherty P: **Designing cell-permeant phosphopeptides to modulate intracellular signaling pathways.** *Biopolymers* 2001, **60**:45-60.
207. Pooga M, Soomets U, Bartfai T, Langel U: **Synthesis of cell-penetrating peptide-PNA constructs.** *Methods Mol Biol* 2002, **208**:225-236.
208. Vidal P, Chaloin L, Heitz A, Van Mau N, Mery J, Divita G, Heitz F: **Interactions of primary amphipathic vector peptides with membranes. Conformational consequences and influence on cellular localization.** *J Membr Biol* 1998, **162**:259-264.
209. Kramer SD, Wunderli-Allenspach H: **No entry for TAT(44-57) into liposomes and intact MDCK cells: novel approach to study membrane permeation of cell-penetrating peptides.** *Biochim Biophys Acta* 2003, **1609**:161-169.
210. Cooper A, Shaul Y: **Recombinant viral capsids as an efficient vehicle of oligonucleotide delivery into cells.** *Biochem Biophys Res Commun* 2005, **327**:1094-1099.
211. Derossi D, Calvet S, Trembleau A, Brunissen A, Chassaing G, Prochiantz A: **Cell internalization of the third helix of the Antennapedia homeodomain is receptor-independent.** *J Biol Chem* 1996, **271**:18188-18193.
212. Berlose JP, Convert O, Derossi D, Brunissen A, Chassaing G: **Conformational and associative behaviours of the third helix of antennapedia homeodomain in membrane-mimetic environments.** *Eur J Biochem* 1996, **242**:372-386.
213. Dathe M, Schumann M, Wieprecht T, Winkler A, Beyermann M, Krause E, Matsuzaki K, Murase O, Bienert M: **Peptide helicity and membrane surface charge modulate the balance of electrostatic and hydrophobic interactions with lipid bilayers and biological membranes.** *Biochemistry* 1996, **35**:12612-12622.
214. Lindberg M, Jarvet J, Langel U, Graslund A: **Secondary structure and position of the cell-penetrating peptide transportan in SDS micelles as determined by NMR.** *Biochemistry* 2001, **40**:3141-3149.
215. Magzoub M, Kilk K, Eriksson LE, Langel U, Graslund A: **Interaction and structure induction of cell-penetrating peptides in the presence of phospholipid vesicles.** *Biochim Biophys Acta* 2001, **1512**:77-89.
216. Huang CJ, Chen YH, Ting LP: **Hepatitis B virus core protein interacts with the C-terminal region of actin-binding protein.** *J Biomed Sci* 2000, **7**:160-168.
217. Gerace L, Foisner R: **Integral membrane proteins and dynamic organization of the nuclear envelope.** *Trends Cell Biol* 1994, **4**:127-131.
218. Holaska JM, Kowalski AK, Wilson KL: **Emerin caps the pointed end of actin filaments: evidence for an actin cortical network at the nuclear inner membrane.** *PLoS Biol* 2004, **2**:E231.
219. Benmerah A, Scott M, Poupon V, Marullo S: **Nuclear functions for plasma membrane-associated proteins?** *Traffic* 2003, **4**:503-511.
220. Ralle T, Grund C, Franke WW, Stick R: **Intranuclear membrane structure formations by CaaX-containing nuclear proteins.** *J Cell Sci* 2004, **117**:6095-6104.
221. Futaki S, Goto S, Sugiura Y: **Membrane permeability commonly shared among arginine-rich peptides.** *J Mol Recognit* 2003, **16**:260-264.
222. Futaki S, Goto S, Suzuki T, Nakase I, Sugiura Y: **Structural variety of membrane permeable peptides.** *Curr Protein Pept Sci* 2003, **4**:87-96.
223. Caron NJ, Quenneville SP, Tremblay JP: **Endosome disruption enhances the functional nuclear delivery of Tat-fusion proteins.** *Biochem Biophys Res Commun* 2004, **319**:12-20.
224. Fischer R, Waizenegger T, Kohler K, Brock R: **A quantitative validation of fluorophore-labelled cell-permeable peptide conjugates: fluorophore and cargo dependence of import.** *Biochim Biophys Acta* 2002, **1564**:365-374.
225. Chuah MK, Schiedner G, Thorrez L, Brown B, Johnston M, Gillijns V, Hertel S, Van Rooijen N, Lillcrap D, Collen D, et al.: **Therapeutic factor VIII levels and**

- negligible toxicity in mouse and dog models of hemophilia A following gene therapy with high-capacity adenoviral vectors.** *Blood* 2003, **101**:1734-1743.
226. Braun H, Boller K, Lower J, Bertling WM, Zimmer A: **Oligonucleotide and plasmid DNA packaging into polyoma VP1 virus-like particles expressed in *Escherichia coli*.** *Biotechnol Appl Biochem* 1999, **29 ( Pt 1)**:31-43.
227. Le Pogam S, Chua PK, Newman M, Shih C: **Exposure of RNA templates and encapsidation of spliced viral RNA are influenced by the arginine-rich domain of human hepatitis B virus core antigen (HBcAg 165-173).** *J Virol* 2005, **79**:1871-1887.
228. Marshall E: **Gene therapy. Viral vectors still pack surprises.** *Science* 2001, **294**:1640.
229. Yoo J, Rho J, Lee D, Shin S, Jung G: **Hepatitis B virus vector carries a foreign gene into liver cells in vitro.** *Virus Genes* 2002, **24**:215-224.
230. Mi Z, Lu X, Mai JC, Ng BG, Wang G, Lechman ER, Watkins SC, Rabinowich H, Robbins PD: **Identification of a synovial fibroblast-specific protein transduction domain for delivery of apoptotic agents to hyperplastic synovium.** *Mol Ther* 2003, **8**:295-305.
231. Neurath AR, Kent SB, Strick N, Parker K, Courouce AM, Riottot MM, Petit MA, Budkowska A, Girard M, Pillot J: **Antibodies to synthetic peptides from the pre-S1 and pre-S2 regions of one subtype of the hepatitis B virus (HBV) envelope protein recognize all HBV subtypes.** *Mol Immunol* 1987, **24**:975-980.
232. Birkett A, Lyons K, Schmidt A, Boyd D, Oliveira GA, Siddique A, Nussenzweig R, Calvo-Calle JM, Nardin E: **A modified hepatitis B virus core particle containing multiple epitopes of the *Plasmodium falciparum* circumsporozoite protein provides a highly immunogenic malaria vaccine in preclinical analyses in rodent and primate hosts.** *Infect Immun* 2002, **70**:6860-6870.
233. Tang DC, DeVit M, Johnston SA: **Genetic immunization is a simple method for eliciting an immune response.** *Nature* 1992, **356**:152-154.
234. Alessandri G, Emanuelli C, Madeddu P: **Genetically engineered stem cell therapy for tissue regeneration.** *Ann N Y Acad Sci* 2004, **1015**:271-284.
235. Cooper A, Paran N, Shaul Y: **The earliest steps in hepatitis B virus infection.** *Biochim Biophys Acta* 2003, **1614**:89-96.
236. Pontow SE, Heyden NV, Wei S, Ratner L: **Actin cytoskeletal reorganizations and coreceptor-mediated activation of rac during human immunodeficiency virus-induced cell fusion.** *J Virol* 2004, **78**:7138-7147.
237. Seksek O, Biwersi J, Verkman AS: **Translational diffusion of macromolecule-sized solutes in cytoplasm and nucleus.** *J Cell Biol* 1997, **138**:131-142.
238. Luby-Phelps K: **Cytoarchitecture and physical properties of cytoplasm: volume, viscosity, diffusion, intracellular surface area.** *Int Rev Cytol* 2000, **192**:189-221.
239. Carter GC, Rodger G, Murphy BJ, Law M, Krauss O, Hollinshead M, Smith GL: **Vaccinia virus cores are transported on microtubules.** *J Gen Virol* 2003, **84**:2443-2458.
240. Suomalainen M, Nakano MY, Boucke K, Keller S, Greber UF: **Adenovirus-activated PKA and p38/MAPK pathways boost microtubule-mediated nuclear targeting of virus.** *Embo J* 2001, **20**:1310-1319.
241. Suomalainen M, Nakano MY, Keller S, Boucke K, Stidwill RP, Greber UF: **Microtubule-dependent plus- and minus end-directed motilities are competing processes for nuclear targeting of adenovirus.** *J Cell Biol* 1999, **144**:657-672.
242. Kallewaard NL, Bowen AL, Crowe JE, Jr.: **Cooperativity of actin and microtubule elements during replication of respiratory syncytial virus.** *Virology* 2005, **331**:73-81.
243. de Soultrait VR, Caumont A, Durrens P, Calmels C, Parissi V, Recordon P, Bon E, Desjobert C, Tarrago-Litvak L, Fournier M: **HIV-1 integrase interacts with yeast microtubule-associated proteins.** *Biochim Biophys Acta* 2002, **1575**:40-48.
244. Seifer M, Hamatake R, Bifano M, Standring DN: **Generation of replication-competent hepatitis B virus nucleocapsids in insect cells.** *J Virol* 1998, **72**:2765-2776.
245. Nakabayashi H, Taketa K, Miyano K, Yamane T, Sato J: **Growth of human hepatoma cells lines with differentiated functions in chemically defined medium.** *Cancer Res* 1982, **42**:3858-3863.

246. Sambrook J, Russell DW: *Molecular Cloning: A Laboratory Manual.*: Cold Spring Harbor Laboratory Press, Cold Spring Harbor, New York 11803-2500, USA.; 2001.
247. Mullis KB, Faloona FA: **Specific synthesis of DNA in vitro via a polymerase-catalyzed chain reaction.** *Methods Enzymol* 1987, **155**:335-350.
248. Pyra H, Boni J, Schupbach J: **Ultrasensitive retrovirus detection by a reverse transcriptase assay based on product enhancement.** *Proc Natl Acad Sci U S A* 1994, **91**:1544-1548.
249. Birnboim HC, Doly J: **A rapid alkaline extraction procedure for screening recombinant plasmid DNA.** *Nucleic Acids Res* 1979, **7**:1513-1523.
250. Vogelstein B, Gillespie D: **Preparative and analytical purification of DNA from agarose.** *Proc Natl Acad Sci U S A* 1979, **76**:615-619.
251. Sanger F, Nicklen S, Coulson AR: **DNA sequencing with chain-terminating inhibitors.** *Proc Natl Acad Sci U S A* 1977, **74**:5463-5467.
252. Dorko K, Freeswick PD, Bartoli F, Cicalese L, Bardsley BA, Tzakis A, Nussler AK: **A new technique for isolating and culturing human hepatocytes from whole or split livers not used for transplantation.** *Cell Transplant* 1994, **3**:387-395.
253. Sauer IM, Schwartlander R, Schmid J, Efimova E, Vondran FWR, Kehr D, Pless D, Brandenburg B, Hildt E, Neuhaus P: **The SlideReactor – a simple hollow-fiber based bioreactor suitable for light microscopy.** *in press Artificial Organs* 2004.
254. BD-Biosciences: **Instruction Manual of Baculo Expression Vector System.** [http://www.bdbiosciences.com/pharming/en/products/display\\_product.php?keyID=72](http://www.bdbiosciences.com/pharming/en/products/display_product.php?keyID=72) 2005.
255. Begemann M, Policar M: **Pneumococcal vaccine failure in an HIV-infected patient with fatal pneumococcal sepsis and HCV-related cirrhosis.** *Mt Sinai J Med* 2001, **68**:396-399.
256. Laemmli UK: **Cleavage of structural proteins during the assembly of the head of bacteriophage T4.** *Nature* 1970, **227**:680-685.
257. Stray SJ, Ceres P, Zlotnick A: **Zinc ions trigger conformational change and oligomerization of hepatitis B virus capsid protein.** *Biochemistry* 2004, **43**:9989-9998.
258. Schreiber AB, Haimovich J: **Quantitative fluorometric assay for detection and characterization of Fc receptors.** *Methods Enzymol* 1983, **93**:147-155.
259. EMBOSS: **European Molecular Biology Open Source Software Suite - Charge Plot.** <http://www.hgmp.mrc.ac.uk/Software/EMBOSS/Apps/charge.html> 2004.

## VII ABBREVIATIONS

Å	Angstrom	NLS	nuclear localization signal
aa	amino acid	NPC	nuclear pore complex
ATP	adenosine triphosphate	nt	nucleotide(s)
bp	base pair	OD	optical density
BSA	bovine serum albumin	ORF	open reading frame
ccc	covalently closed circular	p17, p21...	protein of 17, 21... kDa
CLSM	Confocal Laser Scanning Microscope	PHH	primary human hepatocytes
CPP	cell permeable or penetrating peptide	pol	polymerase
Cy3	Indocarbocyanine	pgRNA	pregenomic ribonucleic acid
Cy5	Indodicarbocyanine	PAGE	polyacrylamide gel electrophoreses
Da	Dalton	PKC	protein kinase C
DAPI	diamidino-2-phenylindol dihydrochloride	PMSF	phenylmethylsulfonylfluorid
DEPC	diethylpyrocarbonate	PTD	protein transduction domain
DHBV	duck hepatitis B virus	PVDF	polyvinylendifluorid
DMEM	DULBECCOs Modified EAGLE Medium	RNA	ribonucleic acid
DMSO	dimethylsulfoxide	rpm	rounds per minute
DNA	deoxyribonucleic acid	RT	room temperature
ECL	enhanced chemoluminescence	Sf	<i>Spodoptera frugiperda</i>
EDTA	ethylenediamin- tetraaceticacid	SDS	sodium dodecyl sulfate polyacrylamide
EGTA	[ethylenbis(oxyethylenitrilo)] tetraaceticacid	SV 40	simian virus 40
ELISA	enzyme-linked immunosorbent assay	T	triangulation number
endo	endogen	TLM	translocation motif
EM	electron microscope	TRIS	tris-(hydroxymethyl) - aminomethane
ER	endoplasmatic reticulum	U	unit
et al.	et alii, latin, meaning 'and others'	V	volt
FITC	fluorescein isothiocyanat	VLP	virus like particle
GFP	green fluorescent protein	WHBV	woodchuck hepatits B virus
x g	gravitation	wt	wildtype
HBc	hepatitis B core protein		
HBs (L, M, S)	hepatitis B surface protein (large, middle and small)		
HBV	hepatitis B virus		
HIV	human immunodeficiency virus		
HSV-1	herpes simplex virus type 1		
Huh7	human hepatoma (carcinoma) cell line 7		
IF	immunofluorescence		
kb	kilo bases		
MAB	monoclonal antibody		
min	minute		
mRNA	messenger ribonucleic acid		
MTS	membrane translocating sequence		

## VIII FIGURE INDEX

Figure 1: Selection of applications for peptide-mediated translocation.....	9
Figure 2: Structure and characteristics of TLM.....	10
Figure 3: Model of the endosomal processing of hepadnaviral particles .....	12
Figure 5: A schematic illustration of the HBV infection .....	17
Figure 6: Transcriptional and translational organization of HBV.....	19
Figure 7: Structure of the Hepatitis B capsid .....	21
Figure 8: HBV core protein sequence and charge plot.....	23
Figure 10: Schema of HBV capsid assembly.....	24
Figure 11: Secondary structure of HBV epsilon signal on pgRNA. ....	27
Figure 12: Polymerase recognizes the HBV pgRNA .....	28
Figure 13: Entry and uncoating mechanisms of selected viruses .....	31
Figure 14: Structural features of wildtype and TLM-capsid constructs. ....	36
Figure 15: TLM-core fusion proteins form properly assembled core.....	37
Figure 16: Effect of TLM insertion on capsid formation.....	38
Figure 17: Fusion of the TLM to the core generates cell-permeable cores .....	40
Figure 18: Schema of in vitro packaging of plasmid DNA into capsids. ....	41
Figure 19: In vitro packaging of plasmid DNA into capsids. ....	43
Figure 20: Quantification of packaged and protected plasmid DNA .....	44
Figure 21: Analyzing the dimerization of two TLM peptides.....	46
Figure 22: Structural features of full-length wt and TLM-capsid.....	47
Figure 23: Cell permeability comparison of different TLM capsids. ....	49
Figure 24: Detailed view of inverse double TLM capsid cell permeability. ....	50
Figure 25: Kinetics of inverse double TLM capsid cell permeability.....	51
Figure 26: Life cell assay to observe the cell permeability of inverse double TLM capsids ....	52
Figure 27: Non-endocytotic uptake of TLM capsids.....	54
Figure 28: Influence of low temperature on the TLM capsid translocation .....	56
Figure 29: Model of cell-permeable capsids.....	58
Figure 30: Baculovirus constructs and the principle of the <i>in vivo</i> packaging .....	59
Figure 31: Baculovirus infection of Sf9 cells to produce nucleocapsids.....	60
Figure 32: Packaging of active HBV polymerase into nucleocapsids. ....	61
Figure 33: Purified TLM nucleocapsids expressed from triple infected insect cells.....	63
Figure 34: Fully assembled TLM nucleocapsids are able to translocate into Huh7. ....	64
Figure 35: TLM nucleocapsids are able to translocate into PHH. ....	65
Figure 36: Fully assembled cell permeable TLM nucleocapsids translocation.....	67
Figure 37: Efficient gene transfer by cell permeable TLM nucleocapsids.....	68
Figure 38: Gene transfer in Huh7 cells and PHH) .....	69
Figure 39: Efficient gene transfer into primary human hepatocytes .....	71
Figure 40: Cytoplasmic trafficking of fully assembled TLM core particles.....	72
Figure 41: Cytosolic interaction partner of hepatitis B virus capsids .....	74
Figure 42: Nucleocapsids are unable to enter isolated liver cell nuclei. ....	76
Figure 43: Localization of hepatitis B capsids in digitonin-permeabilized cells.....	78
Figure 44: Prediction for double TLM capsid interaction with cell membrane.....	83
Figure 45: Model of TLM capsid translocation via an inverted micelle .....	84
Figure 46: Baculovirus expression system .....	114
Figure 47: Calibrated size exclusion column (preparative superose 6).....	117
Figure 48: Schematic representation of the protein-protein interaction assay.....	122

## IX CURRICULUM VITAE

### BOERRIES BRANDENBURG

Date & Place of Birth: 27. February 1976, Berlin, Germany

Education: 1990–1995 Robert Koch – High school, Berlin  
1995–2002 Freie University Berlin, Major: Biology  
Master thesis, Robert Koch-Institute,  
Berlin, Molecular Virology, Dr. E. Hildt  
2002–2005 Ph.D. thesis, Robert Koch-Institute,  
Berlin, Molecular Virology, Dr. E. Hildt

### PUBLICATIONS

- Beutin L., Kaulfuss S., Cheasty T., **Brandenburg B.**, Zimmermann S., Gleier K., Willshaw G. and Smith H., (2002), Characteristics and association with disease of two major subclones of Shiga toxin producing strains of E. coli O157 that are present among isolates from patients in Germany, *Diagnostic Microbiology and Infectious Disease*, 44(4):337-46.
- Hafner A., **Brandenburg B.** and Hildt E., (2003), Reconstitution of gene expression from a regulatory-protein-deficient hepatitis B virus genome by cell-permeable HBx protein. *EMBO Rep.*, 4,767-773.
- Friedrich B., Wollersheim M., **Brandenburg B.**, Foerste R., Will H. and Hildt E. (2005), Induction of anti-proliferative mechanisms in Hepatitis B virus producing cells; *Journal of Hepatology*, in press.
- Hillemann A., **Brandenburg B.**, Schmidt U., Roos M., Smirnow I., Lemken M., Lauer U. M. and Hildt E. (2005), Protein transduction with bacterial cytosine deaminase fused to the TLM intercellular transport motif induces profound chemosensitivity to 5-fluorocytosine in human hepatoma cells; *Journal of Hepatology*, in press.
- Sauer I.M., Schwartlander R., Schmid J., Efimova E., Vondran F.W.R., Kehr D., Pless D., **Brandenburg B.**, Hildt E. and Neuhaus P. (2005) The SlideReactor – a simple hollow-fiber based bioreactor suitable for light microscopy; *Artificial Organs*, 29(3):264-7.
- Stoeckl L., Funk A., Kopitzki A., **Brandenburg B.**, Oess S., Hans Will H., Sirma H. and Hildt E. (2005), Identification of a novel structural motif crucial for infectivity of hepatitis B viruses; submitted.
- Brandenburg B.**, Stoeckl L., Gutzeit C., Roos M., Lupberger J., Gelderblom H. and Hildt E. (2005), Cell permeable nucleocapsids as a novel tool for efficient gene transfer in primary human hepatocytes; submitted.
- Brandenburg B.**, Gutzeit C. and Hildt E. (2005), Cytoplasmic trafficking and nuclear uptake of Hepatitis B Virus capsid; manuscript in preparation.

## ORAL PRESENTATIONS

- Brandenburg B.**, Stoeckl L., Gelderblom H., Hofschneider P. H., Hildt E., (2003), Efficient packaging of nucleic acids into cell-permeable nucleocapsids that serve as a novel tool for gene transfer. International HBV Meeting, Bergamo, Italy.
- Brandenburg B.**, Stoeckl L., Gelderblom H., Hofschneider P. H., Hildt E., (2004), Efficient gene transfer mediated by cell-permeable nucleocapsids. Annual Meeting of the German Virological Society (GfV), Tuebingen, Germany.
- Brandenburg B.**, Cindy Gutzeit, Eberhard Hildt (2005), Intracellular trafficking of hepatitis B virus nucleocapsids. Annual Meeting of the German Virological Society (GfV), Hannover, Germany.

## POSTER

- Stoeckl L., **Brandenburg B.**, Hofschneider P. H., Hildt E. (2002) Cell permeable nucleocapsids as a novel tool for safe and efficient gene transfer. Annual meeting of the German Virological Society (GfV), Erlangen, Germany.
- Brandenburg B.**, Stoeckl L., Gelderblom H., Hildt E., (2003), Strategies for packaging of DNA in Virus like Particles. Annual Meeting of the German Virological Society (GfV), Berlin, Germany.
- Brandenburg B.**, Gutzeit C., Luckow A., Hildt E., (2004), The cytoplasmic way of the HBV core. Annual Meeting of the German Virological Society (GfV), Tuebingen, Germany.
- Lupberger J., Schneider M., **Brandenburg B.**, Hildt E., (2004), The isolation and funktional characterisation of the Hepatitis B Virus polymerase. Annual Meeting of the German Virological Society (GfV), Tuebingen, Germany.
- Brandenburg B.**, Stoeckl L., Gelderblom H., Hofschneider P. H., Hildt E., (2004), Efficient packaging of nucleic acids into cell-permeable nucleocapsids that serve as a novel tool for gene transfer. European Association For The Study Of The Liver (EASL), Berlin, Germany.
- Brandenburg B.**, Gutzeit C., Hildt E. (2004), Cell permeable HBV nucleocapsids as a new model to investigate the intracellular trafficking in intact cells, Molecular Biology of Hepatitis B Virus, Boston, USA.
- Brandenburg B.**, Stoeckl L., Gutzeit C., Gelderblom H., Hofschneider P. H., Hildt E., (2004), Efficient packaging of nucleic acids into cell-permeable nucleocapsids that serve as a novel tool for gene transfer. Molecular Biology of Hepatitis B Virus, Boston, USA.

## SCHOLARSHIPS/AWARDS

- 01/2002 – 03/2005     German National Academic Foundation – Fellowship  
(Studienstiftung des Deutschen Volkes)
- 07/2003 – 03/2005     e-Fellows-scholarship (supported by McKinsey, Roche, Siemens and  
Deutsche Bank)
- 10/2004     Poster prize, International Meeting – Molecular Biology of HBV, Boston, USA.



## **X DANKSAGUNG**

Als erstes möchte ich mich besonders bei Dr. Eberhard Hildt bedanken, der es mir ermöglichte diese Doktorarbeit in seinem Labor durchzuführen.

Vielen Dank für Deine Unterstützung und Betreuung, die Diskussionsbereitschaft, die positive Energie sowie die Möglichkeit, mich so frei entfalten zu können. Es gab nie einen Tag an dem ich nicht in die ewig (zu) hellen Hallen der NG1 kommen wollte (außer vielleicht um 8:30 Uhr zum Seminar – wessen Idee war das eigentlich...). Danke für die von Dir gewährte große Eigenverantwortung. Ich konnte viele wichtige Erfahrungen mit meinen Praktikanten und Diplomanden, sowie auf Kongressen sammeln.

*Lucundi acti labores!* Cicero

Bei den Herren Prof. Dr. Georg Pauli und Prof. Dr. Volker Erdmann möchte ich mich bedanken, für Ihre Bereitschaft diese Arbeit zu begutachten und vor dem Fachbereich zu vertreten.

Mein besonderer Dank geht an Dr. Lars Stöckl, der mich in die Welt der Kapside einführte und mir bis heute die Freundschaft hält. Es brauchte seine Zeit um in Deinen Fußstapfen zu gehen.

Ganz herzlich danke ich meinen Diplomandinnen und Diplomanden und im Besonderen Cindy Gutzeit und Jeannine Günther die zum Entstehen dieser Dissertation beigetragen haben. Es war nicht immer ein Spaziergang aber gelaufen ist es super um nicht zu sagen, es hat gerockt! Darüber hinaus möchte ich nicht vergessen mich bei den vielen Praktikantinnen und Praktikanten für den regelmäßig viel zu späten „Dienstschluss“ zu entschuldigen. Vielen Dank für Eure Mühen: Annika Röske, Anja Luckow, Franziska Knopf, Julia Wiethaus, Nadine Nippe, Yvonne Baermann und Falko Nagel.

Ein entscheidender Faktor für das Gelingen dieser Arbeit war das sensationell gute Arbeitsklima in unserem Lab. Es war eine Freude mit Euch: Tilmann Bürckstümmer, Joachim Lupberger, Markus Möbs, Malte Kriegs und der ganzen NG1 zu arbeiten, zu diskutieren, zu spielen, zu tanzen, zu lachen, zu wetten und nicht zu letzt anzustoßen.

Ferner möchte ich mich vor allem bei Lars Funke und Ingrid Brandenburg für die Hilfe bei der Korrektur meiner Arbeit bedanken.

...impotent target cells... klang trotzdem gut!

---

Für die exzellente technische Unterstützung bei der Probenaufarbeitung für das Elektronenmikroskop sowie am selbigen danke ich herzlich Freya Kaulbars and Andrea Maennel.

Als sehr fruchtbar und angenehm erwies sich auch die Zusammenarbeit mit der Arbeitsgruppe von Dr. Igor Sauer in der Experimentellen Chirurgie der Charité. Vielen dank Ruth Schwartländer für die schönen primären humanen Hepatocyten.

Ein besonderen Dank gilt meinen Eltern sowie der Studienstiftung des Deutschen Volkes für die umfangreiche finanzielle und geistige Unterstützung.

Der mit Abstand größte Dank gebührt Angela Hafner. Das Zusammen-sein, Leben, Arbeiten, Lachen und Vorankommen ist wunderbar mit Dir. Vielen lieben Dank für Deine großartige Unterstützung in allen Lebenslagen! Ich freue mich auf unser nächstes Kapitel in Boston.

\*\*\*